ADPT: Cup Handle detected on 26 Jun 2026

ADPT has formed a cup-handle pattern with clonoSEQ (its next-generation sequencing MRD test) featured in 33 ASCO and EHA conference presentations. The stock sits at $20.25, trading between support at $15.90 and resistance at $18.08, with a measured move target of $22.81. Pattern quality scores are strong across structure (15/15), breakout (13/13), and volume (12/12), totaling 81/98 overall with 54.49% win probability. Volume ratio of 1.09x confirms healthy breakout confirmation potential. RSI at 70.87 signals overbought conditions warrants monitoring.

Q1 2026 revenue reached $70.9 million (95% MRD-driven) with clonoSEQ test volume up 41% YoY to 32,595 tests. Full-year MRD revenue guidance was raised to $260–$270 million, signaling strong operational momentum. On June 20, 2026, ADPT announced plans to separate MRD and Immune Medicine businesses and completed a $300 million convertible notes offering, representing a meaningful shift in capital allocation and positioning each segment for standalone value. MRD has achieved significant scale, expanded reimbursement, strengthened clinical evidence, and reached profitability. This corporate restructuring, combined with proven diagnostic adoption and robust revenue growth, is driving the recent 43% one-month price appreciation.

Cup-handle breakdown targets $22.81 conservatively (12.6% from current price). Successful breakout requires volume confirmation above the handle resistance at $18.08, followed by sustained daily closes above that level. The 54.49% win probability suggests pattern validity though not exceptional. Invalidation occurs decisively below support at $15.90; failure to close above $18.08 on expanded volume would negatively impact pattern setup. Earnings on August 4, 2026 represent the next major catalyst; pattern typically needs 4-8 weeks to develop post-breakout. Volatility at 75.21% (elevated) and beta at 1.05 suggest moderate market sensitivity.

Critical warning: RSI at 70.87 indicates overbought conditions—typically precedes pullback in biotech stocks. Valuation risk is substantial: P/S ratio of 9.5x exceeds US Life Sciences industry average of 3.8x and fair ratio of 4.2x, raising downside risk if sentiment cools. Genentech partnership terminated February 2026; raised MRD guidance must now offset lost partnership revenue and support profitability narrative. Ongoing group-level losses and reliance on key partnerships present execution risk. Stock has already gained 43% in one month; profit-taking pressure likely near resistance. Earnings report August 4 could trigger volatility if growth expectations aren't met given stock's sharp recent run.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.